Ondine Biomedical (LSE:OBI) has temporarily paused trading in its shares on AIM through a so-called capital access window while it pursues an equity fundraise, weeks after reporting positive topline results from its US Phase 3 trial of the Steriwave nasal photodisinfection treatment. The Canadian life sciences company, which published its interim results on 30 September 2026, said cash was expected to last only into the middle of the fourth quarter and that it needed to secure additional funding in the near term.

What the company does

Ondine develops light-activated antimicrobial therapies, which it calls photodisinfection, to prevent and treat infections. Its lead product, Steriwave, is used for nasal decolonisation to reduce the risk of infection in surgical and intensive care patients. It is authorised in Canada, the UK and certain other markets, but in the United States it is limited to investigational use and does not yet have Food and Drug Administration approval.

Latest developments

On 1 September 2026 Ondine announced that its LANTERN Phase 3 study, which enrolled 5,188 patients, met its primary efficacy endpoint. The company reported a 40.5% relative reduction in the risk of surgical site infection within 30 days compared with standard of care, and said no treatment-related serious adverse events were identified in the topline analysis. Subject to funding and further analysis, it is targeting a pre-submission meeting with the FDA in the first quarter of 2027 and a New Drug Application in mid-2027.

Commercially, the company has reported a series of deployments. In July a first Scottish hospital adopted Steriwave, in September it announced a pilot with Mexico's largest private hospital network and deployment in five southern Ontario hospitals, and on 29 September it said it was advancing NHS intensive care market access with partner Mela. A study at Leeds reported a 78% reduction in surgical site infections in complex brain surgery compared with the previous mupirocin-based period.

The capital access window, which took effect on 30 September, follows changes to AIM rules announced in August 2026. Ondine said the planned raise, which will include a retail offer, would fund full trial analyses, FDA engagement, commercial pilots, sales and marketing, working capital and the strengthening of its leadership team. Neither the amount nor the price had been disclosed at the time of the announcement.

Financial picture

For the six months to 30 June 2026, Ondine reported revenue of C$1.25 million, up 23% from C$1.01 million, with gross margin stable at 65%. Research and development spending rose to C$11.5 million as the Phase 3 trial ran its course, and the net loss widened to C$16.2 million from C$12.6 million. Cash fell to C$5.3 million at 30 June from C$10.6 million at the end of 2025, despite a fundraise of about £5 million in the spring. The company expects costs to fall materially as trial activity shifts to analysis and regulatory work. No dividend is paid.

Sector and index context

Ondine is one of a number of clinical-stage healthcare companies on the FTSE AIM All Share Index whose valuations hinge on regulatory milestones. Its focus is on hospital-acquired infections, where it positions photodisinfection as an alternative to antibiotic-based nasal treatments such as mupirocin.

Key risks

Funding is the most immediate risk, given the short cash runway, and any raise could be significantly dilutive. FDA approval is not assured, and the full LANTERN analysis is still ongoing. Commercial revenue remains small relative to costs.

What to watch next

The key near-term event is the outcome of the fundraise and the resumption of trading. Beyond that, investors will watch for full LANTERN data, the FDA meeting in early 2027 and further hospital adoptions.